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ess: giichi@kch.hosp.goSummary Existence of anti-granulocyte-macrophage colony-stimulating factor
(GM-CSF) neutralizing antibody and treatment with recombinant GM-CSF are new
topics in idiopathic pulmonary alveolar proteinosis (PAP). We have hypothesized
inhaled GM-CSF is effective and neutralizing capacity of GM-CSF, not concentration
of anti-GM-CSF antibody in serum reflect disease severity.
A 57-year-old female smoker with idiopathic PAP was treated with inhaled GM-
CSF. The response to the treatment was evaluated by diffusing capacity for carbon
monoxide (DLCO), alveolar-arterial oxygen gradient ([A-a]DO2). Conventional serum
markers, including KL-6, surfactant apoprotein (SP)-A, SP-D, carcino-embryonic
antigen and cytokeratin fragment 19 (CYFRA), and concentration of anti-GM-CSF
antibody were examined. The neutralizing capacity of GM-CSF in serum was
evaluated using a GM-CSF dependent cell line, TF-1.
Ground glass opacity disappeared at the end of the treatment. Her DLCO, [A-
a]DO2 remarkably improved after treatment. The neutralizing capacity of GM-CSF
declined in line with disease remission and it correlated significantly with DLCO
(P ¼ 0:0137). The concentration of anti-GM-CSF antibody had no significant relation
with disease severity and serum markers including neutralizing capacity. Conven-
tional serum markers other than CYFRA showed no significant correlation with
DLCO.Elsevier Ltd. All rights reserved.
-252-3021.
.jp (Y. Inoue).
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T. Arai et al.1228Inhaled GM-CSF was effective for idiopathic PAP. Serial measurement of
neutralizing capacity of GM-CSF was useful to evaluate disease severity and the
anti-GM-CSF antibody was proved to be a causative factor for PAP. In the future,
inhaled GM-CSF may replace whole lung lavage and response to GM-CSF and its
optimal amount may be decided by the capacity.
& 2004 Elsevier Ltd. All rights reserved.Introduction
The pathogenesis of pulmonary alveolar proteinosis
(PAP) is supposed to be through impaired alveolar
macrophage function caused by deficiency of
granulocyte-macrophage colony-stimulating factor
(GM-CSF) in alveolar spaces, induced by anti-GM-
CSF antibody.1–4 In 1996, Seymour et al. 5 reported
that subcutaneous administration of GM-CSF was
effective for PAP, and the result was confirmed in
two published prospective phase II trials.6,7 We
hypothesize that inhaled GM-CSF in a patient with
severe PAP are effective through a result of the
experiment using GM-CSF knockout mouse 8 and
that neutralizing capacity of GM-CSF in serum is a
novel and useful serum marker to reflect disease
severity.Methods
Patient and clinical course before GM-CSF
inhalation
A 57-year-old female smoker suffered from cough
with white sputum and progressive shortness of
breath on exertion for 4 months. High-resolution
computed tomography (HRCT) of the chest showed
crazy paving appearance. Diffusing capacity for
carbon monoxide (DLCO) was reduced at 34.2% of
the predicted value and the arterial oxygen tension
(PaO2) on room air was 43 Torr. She was diagnosed
with idiopathic PAP from the findings of bronchoal-
veolar lavage and transbronchial lung biopsy.2 Anti-
GM-CSF antibody was detected in the serum and
bronchoalveolar lavage fluid. One month later, her
disease did not improved and she was treated with
GM-CSF inhalation.
GM-CSF inhalation
Bacterially- synthesized recombinant GM-CSF (Leu-
comax; Schering-Plough, Baulkham Hills, Australia)
of 125mcg was nebulized with a PARI LC PLUS
nebulizer set (Pari Respiratory Equipment, Inc.,
Richmond, VA, USA) twice-a-day, 7 days a week,
followed by a treatment-free week, repeated for24 weeks. This method is based on the early study
for cancer patients.9
Assay of the neutralizing capacity of GM-CSF
and concentration of anti-GM-CSF antibody
in the serum
GM-CSF dependent TF-1 cells were cultured with or
without recombinant human GM-CSF, in the pre-
sence of serum from idiopathic PAP or control
serum. Survival of TF-1 cells was evaluated using
MTT assay as described previously.2 The neutraliz-
ing capacity was defined as the following equation:
Neutralizing capacity (%)=[1(AB)/(CD)]
100, where A, B, C and D are the absorbance of
TF-1 cells grown with serum from PAP and GM-CSF,
with serum from PAP and no GM-CSF, with control
serum and GM-CSF, and with control serum and no
GM-CSF, respectively.
Concentration of anti-GM-CSF antibody in serum
and BALF was measured by the enzyme-linked
immunosorbent assay previously described.10
Statistical methods
Correlation of variables was assessed using the
Spearman rank correlation coefficient. Linear re-
gression lines were calculated using the least-
squares method. The P value is significant, if it is
less than 0.05.Results
Response of GM-CSF inhalation and serial
change of neutralizing capacity, anti-GM-CSF
antibody level and the other serum markers
After the first 2 weeks of the treatment [A-a]DO2
and DLCO improved (Fig. 1a). Ground glass opacity
on HRCTalmost completely disappeared at the final
inhalation. This therapy was tolerable without
apparent toxicity.
The levels of serum cytokeratin fragment 19
(CYFRA), KL-6, carcino-embryonic antigen (CEA),
surfactant apoprotein (SP)-A, SP-D and lactate
dehydrogenase (LDH), conventional serum markers
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Figure 1 (a) Diffusing capacity of carbon monoxide
(DLCO) increased and alveolar-arterial oxygen gradient
([A-a]DO2) decreased after the GM-CSF inhalation. (b)
The levels of serum cytokeratin fragment 19 (CYFRA) and
KL-6 declined rapidly during the first two weeks of the
granulocyte macrophage colony-stimulating factor (GM-
CSF) inhalation therapy. Neutralizing capacity of GM-CSF
in serum apparently decreased gradually, although
concentration of anti-GM-CSF antibody did not decline
remarkably. The cut off level for abnormal elevation was
500U/ml for KL-6 and 2.8 ng/ml for CYFRA.
Neutralizing capacity of GM-CSF in PAP 1229for PAP, rapidly decreased two weeks after the first
inhalation (Fig. 1b). Neutralizing capacity of GM-
CSF in serum apparently decreased gradually,
although concentration of anti-GM-CSF antibody
did not decline remarkably (Fig. 1b).Correlation between neutralizing capacity
and disease severity
Correlation between serum markers and disease
severity markers, [A-a]DO2 and DLCO, was analyzed
(data not shown). The neutralizing capacity had
significant correlation with DLCO (n ¼ 7; rho ¼
0:8571; P ¼ 0:0137) and levels of SP-A, KL-6,
CEA and CYFRA, but not with [A-a]DO2. Serum
anti-GM-CSF antibody concentration was correlated
neither with the disease severity markers nor withserum markers including neutralizing capacity of
GM-CSF. Conventional serum markers other than
CYFRA (n ¼ 7; rho ¼ 0:8571; P ¼ 0:0137) showed
no significant correlation with DLCO.Discussion
The concentration of anti-GM-CSF antibody and
neutralizing capacity of GM-CSF were evaluated as
new serum markers in the patient successfully
treated with inhaled GM-CSF. The anti-GM-CSF
antibody level did not decline significantly and it
was not correlated with any of the serum and
disease severity markers in our case. The neutraliz-
ing capacity of GM-CSF kept decreasing gradually
and it was significantly correlated with DLCO, and
with serum markers, KL-6, SP-A, CEA and CYFRA.
These results suggest that it is useful to assess the
disease severity of individual PAP patients during
the clinical courses and neutralization of GM-CSF is
fundamental for pathogenesis of PAP.
Seymour 10 also showed that the concentration of
anti-GM-CSF antibody is not correlated with the
respiratory functions of PAP patients, suggesting
that the neutralizing capacity of the antibody is
variable in the individual cases. If so, concentration
of anti-GM-CSF antibody should correlate with
neutralizing capacity of GM-CSF in each PAP
patient, but we could not find significant correla-
tion between these two markers in the presented
case. Anti-GM-CSF antibodies are known to be
polyclonal 1 in each case, and the binding capacity
of each antibody should be different. The antibody
with strong binding capacity to GM-CSF will be
present more as a form of immune-complex with
GM-CSF and be cleared more rapidly through
opsonization by mature macrophage activated
by administered GM-CSF than one with weak
binding capacity. Thus the antibody with weak
binding capacity persisted longer than the one with
strong capacity and neutralizing capacity of GM-
CSF in serum gradually decreased, even if the
concentration of the antibody did not decrease
significantly.
We conclude that inhaled GM-CSF is effective
treatment for idiopathic PAP, and that the mea-
surement of the neutralizing capacity is useful to
evaluate disease severity as a new serum marker
reflecting the activity of a causative factor, anti-
GM-CSF antibody. We anticipate that the response
to GM-CSF and its optimal amount in each PAP
patient may be decided using this new marker in
addition to the other serum markers.
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